Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma

NCT04903899 is registered in ClinicalTrials.gov with Jakob Stenman as lead sponsor.

NCT NCT04903899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04903899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
Lead sponsor
Jakob Stenman
Phase
Phase 2
Overall status
Recruiting
Start date
May 19, 2021
Completion date
May 20, 2031
Enrollment
24 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma, neuroblastoma recurrent